EUCTR2021-005344-30-NL进行中(未招募)1 期
TETRA-pilot: Testosterone in transgender women after vaginoplasty: a dose-finding and feasibility pilot study - TETRA-pilot
Amsterdam UMC, location VUmc0 个研究点目标入组 10 人开始时间: 2022年5月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •-Start of gender affirming hormone therapy at or after 18 years of age
- •-Current use of estradiol therapy with good compliance for at least six months
- •-Underwent vaginoplasty at least 6 months ago
- •-Sufficient knowledge of the Dutch language
- •-BMI 18-35 kg/m2
- •-Testosterone levels <0.8 nmol/l measured since vaginoplasty
- •-To participant in optional vaginal pulse amplitude measurement: minimal self-reported vaginal depth of five centimeters
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-No regular follow-up visits at the clinic for gender dysphoria in the past four years
- •-Current use of testosterone therapy
- •-Current untreated clinical depression
- •-Severe familial dyslipidemia (e.g. Familial Hypercholesterolemia)
- •-Serum estradiol concentration lower than 150 pmol/l or higher than 700 pmol/L the VUmc reference range (150-700 pmol/L) at last visit prior to baseline.
- •-Mental health issues that prevent participation
- •-Current use of anticoagulation treatment or corticosteroids
- •-Any of the following contraindications for the use of testosterone gel (Tostran®): Known, past or suspected breast cancer; Known or suspected estrogen-dependent malignant tumours (e.g genital tract carcinoma); Acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal (<2.5xULN); Porphyria; Cerebral hemorrhage; Known hypersensitivity to the active substances or to any of the excipients (Propylene glycol, Ethanol anhydrous, Isopropyl alcohol, Oleic acid, Carbomer 1382, Trolamine, Butylhydroxytoluene (E321), Hydrochloric acid (used for pH adjustment)); Interfering medication (SPC).
研究者
相似试验
已完成
2 期
TETRA-pilot: Testosterone in transgender women after vaginoplasty: a dose-finding and feasibility pilot studygender-affirming hormone treatmentHypogonadism10014701NL-OMON51335niversitair Medisch Centrum10
尚未招募
Unknown
Total testosterone level in women undergoing ovarian stimulation and its impact on Assisted Reproductive Technique cyclesCTRI/2023/11/059971I
已完成
不适用
Administration of testosterone to women with androgen insensitivity: a study of the role of androgen replacement on psychological functioutritional, Metabolic, Endocrine: Androgen replacementNutritional, Metabolic, EndocrineISRCTN17551969Department of Health (UK)20
已完成
不适用
Effect of transdermal testosterone replacement in hypogonadal men with decreased insulin sensitivityHypogonadal men with decreased insulin sensitivityNutritional, Metabolic, EndocrineTesticular hypofunctionISRCTN45741714ProStrakan Pharmaceuticals (UK)320
进行中(未招募)
不适用
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failureEUCTR2005-002607-17-DEProstrakan Pharmaceuticals Ltd520
